サンプル依頼リスト カート
  • English
  • Korean
表紙：百日咳ワクチンの世界市場レポート 2024年
市場調査レポート
商品コード
1415770

百日咳ワクチンの世界市場レポート 2024年

Pertussis Vaccine Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
百日咳ワクチンの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

百日咳ワクチン市場規模は近年着実に成長しています。2023年の52億6,000万米ドルから2024年には55億米ドルへと、CAGR4.4％で拡大します。実績期間の成長は、疾病の流行、予防接種プログラム、小児ワクチン接種、規制当局の承認に起因しています。

百日咳ワクチンの市場規模は、今後数年間で安定した成長が見込まれます。2028年にはCAGR3.6％で63億3,000万米ドルに成長します。予測期間の成長は、ブースターワクチン接種、妊産婦への予防接種、ヘルスケア従事者への予防接種、世界ヘルスへの取り組みに起因すると考えられます。予測期間の主な動向には、個別化予防接種スケジュール、混合ワクチン、ワクチン公平性への取り組み、予防接種のためのデジタルヘルスなどがあります。

出産率の上昇傾向は、百日咳ワクチン市場の大きな成長促進要因になると予想されます。出産は子供をこの世に誕生させる自然なプロセスであり、妊娠の終わりと新しい生命の始まりを意味します。百日咳ワクチンは、百日咳やその他の重症で生命を脅かす可能性のある病気から子供を守ることを主な対象としています。例えば、2022年5月、米国を拠点とする疾病管理予防センター（CDC）は、2021年の米国の出生数を366万人と報告し、2020年の361万人からわずかに増加しました。さらに、カナダ統計局によると、2021年のカナダでは出生数が2％増加し、その数は2020年の360,552人から2021年には367,684人に増加しました。したがって、出産率の増加は、百日咳ワクチン市場の拡大を推進する重要な要因です。

老人人口の継続的な増加が百日咳ワクチン市場の拡大を促進すると予測されます。老年人口には、通常65歳以上の後期高齢者が含まれます。高齢者人口の拡大は、百日咳ワクチン市場の主要な貢献者です。寿命が延びるにつれて、この深刻な病気から高齢者を守る百日咳ワクチンへの需要が高まっています。例えば、2022年10月、スイスに本部を置く世界保健機関（WHO）は、60歳以上の世界人口が2050年までに倍増し、21億人に達すると予測しました。同時に、80歳以上の人口は2020年から2050年にかけて3倍に増え、4億2600万人に達すると予想されています。その結果、老人人口の増加が百日咳ワクチン市場の成長を促進しています。

2023年の百日咳ワクチン市場で最大の地域は北米でした。百日咳ワクチンレポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の百日咳ワクチン市場、製品タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • DTaP（ジフテリア、破傷風、無細胞百日咳）ワクチン
  • Tdap（破傷風、ジフテリア、百日咳）ワクチン
  • 世界の百日咳ワクチン市場、ワクチンの種類別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 全細胞ワクチン
  • 無細胞ワクチン
  • 世界の百日咳ワクチン市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 子供
  • 大人
  • 幼児
  • 世界の百日咳ワクチン市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 予防接種センター
  • 病院
  • クリニック

第7章 地域および国の分析

  • 世界の百日咳ワクチン市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の百日咳ワクチン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 百日咳ワクチン市場の競合情勢
  • 百日咳ワクチン市場の企業プロファイル
    • Pfizer Inc.
    • Johnson And Johnson Pvt Ltd.
    • Merck And Co. Inc.
    • Novartis AG
    • GlaxoSmithKline plc

第31章 その他の主要および革新的な企業

  • AstraZeneca plc
  • BioNTech SE
  • Moderna Inc.
  • Sinovac Biotech Ltd.
  • CSL Limited
  • Astellas Pharma US Inc.
  • Sanofi Pasteur SA
  • Mitsubishi Tanabe Pharma America Inc.
  • PT Kalbe Farma Tbk
  • CSL Seqirus
  • Walvax Biotechnology Co.Ltd.
  • Biological E. Limited
  • Serum Institute of India
  • Bavarian Nordic AS
  • PT Bio Farma

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12369

“Pertussis Vaccine Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pertussis vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pertussis vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The pertussis vaccine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine; Tdap (Tetanus, Diphtheria and Pertussis) Vaccine
  • 2) By Vaccine Type: Whole-Cell Vaccine; Acellular Vaccine
  • 3) By Application: Children; Adults; Infants
  • 4) By End-User: Vaccination Centers; Hospitals; Clinics
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson Pvt Ltd.; Merck And Co. Inc.; Novartis AG; GlaxoSmithKline plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

The pertussis vaccine is a vaccination designed to provide protection against whooping cough (pertussis), a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. Its purpose is to stimulate the immune system to generate protective antibodies against the pertussis bacterium, thus reducing the risk of infection and the associated symptoms.

The main products related to the pertussis vaccine include the DTaP (diphtheria, tetanus, and acellular pertussis) vaccine and the Tdap (tetanus, diphtheria, and pertussis) vaccine. The DTaP vaccine, which is also known as the DTP vaccine, is a combination vaccine intended to safeguard against three serious bacterial infections such as diphtheria, tetanus, and pertussis (whooping cough). These vaccines are available in both whole-cell and acellular formulations and are administered to individuals of various age groups, including children, adults, and infants. They are typically administered by healthcare professionals at vaccination centers, hospitals, and clinics.

The pertussis vaccine market research report is one of a series of new reports from The Business Research Company that provides pertussis vaccine market statistics, including pertussis vaccine industry global market size, regional shares, competitors with a pertussis vaccine market share, detailed pertussis vaccine market segments, market trends and opportunities and any further data you may need to thrive in the pertussis vaccine industry. This pertussis vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pertussis vaccine market size has grown steadily in recent years. It will grow from $5.26 billion in 2023 to $5.5 billion in 2024 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to disease prevalence, immunization programs, pediatric vaccination, regulatory approvals.

The pertussis vaccine market size is expected to see steady growth in the next few years. It will grow to $6.33 billion in 2028 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to booster vaccination, maternal immunization, immunization for healthcare workers, global health initiatives. Major trends in the forecast period include personalized immunization schedules, combination vaccines, vaccine equity initiatives, digital health for immunization.

The upward trend in childbirth rates is expected to be a significant growth driver for the pertussis vaccine market. Childbirth is the natural process of bringing a child into the world, marking the end of pregnancy and the beginning of a new life. The pertussis vaccine primarily targets children to provide protection against whooping cough and other severe, potentially life-threatening illnesses. For example, in May 2022, the U.S.-based Center for Disease Control and Prevention (CDC) reported 3.66 million births in the United States in 2021, a slight increase from 3.61 million in 2020. Additionally, in 2021, Canada, as per Statistics Canada, recorded a 2% rise in births, with numbers increasing from 360,552 in 2020 to 367,684 in 2021. Hence, the growing prevalence of childbirth rates is a significant factor propelling the expansion of the pertussis vaccine market.

The continuous growth of the geriatric population is anticipated to drive the expansion of the pertussis vaccine market. The geriatric population encompasses individuals in their later stages of life, typically aged 65 and older. The expanding number of older adults is a key contributor to the pertussis vaccine market. As more people enjoy longer lifespans, there is a heightened demand for pertussis vaccines to protect older individuals from this serious disease. For instance, in October 2022, the Switzerland-based World Health Organization projected that the global population of individuals aged 60 years and above is set to double by 2050, reaching 2.1 billion. Simultaneously, the number of individuals aged 80 years or older is expected to triple from 2020 to 2050, totaling 426 million. Consequently, the growing geriatric population is fostering the growth of the pertussis vaccine market.

The restricted availability of pertussis vaccines acts as a constraining factor on the growth of the pertussis vaccines market during the projected period. The limited accessibility to pertussis vaccines has resulted in adverse effects on their distribution and effectiveness, including constrained vaccine accessibility, escalated costs, decreased demand, delayed or incomplete immunization, and global ramifications. For instance, in July 2023, UNICEF (United Nations International Children's Emergency Fund) reported that approximately 14.3 million children did not receive any doses of pertussis vaccines (diphtheria-tetanus-pertussis DTP3) in 2022. Hence, this limited availability is impeding the expansion of the pertussis vaccines market.

Major enterprises engaged in the pertussis vaccine market are actively advancing innovative vaccines and securing regulatory approvals to maintain their market position. For instance, in October 2022, GSK plc., a UK-based pharmaceutical and biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval of BOOSTRIX. BOOSTRIX is a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) vaccine. It is administered during pregnancy to prevent pertussis (whooping cough) in newborn infants and is administered as a single upper arm muscle injection. Boostrix is recognized for its safety and effectiveness in pregnant women and their infants, effectively preventing pertussis, including severe cases of the disease.

In May 2022, GSK plc., a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for a sum of $2.1 billion. This strategic acquisition is a step taken by GSK to broaden its vaccine portfolio, enhance its outreach to patients, bolster its vaccine research and development pipeline, gain access to a potentially groundbreaking technology, and expand its scientific presence in the Boston region. Affinivax Inc. is a U.S.-based biotechnology enterprise specialized in the development of pertussis vaccines.

Major players in the pertussis vaccine market are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, BioNTech SE, Moderna Inc., Sinovac Biotech Ltd., CSL Limited, Astellas Pharma US Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma America Inc., PT Kalbe Farma Tbk, CSL Seqirus, Walvax Biotechnology Co.Ltd., Biological E. Limited, Serum Institute of India, Bavarian Nordic AS, PT Bio Farma, Bharat Biotech International Limited, Takeda Pharmaceutical Company, Panacea Biotec Limited, Beijing Minhai Biotechnology Co. Ltd., Protein Sciences Corporation, Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Gennova Biopharmaceuticals Ltd., Chiron Corporation .

North America was the largest region in the pertussis vaccine market in 2023. The regions covered in pertussis vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pertussis vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pertussis vaccine market consists of sales of adacel, daptacel, infanrix, kinrix, pediarix, pentacel and quadracel. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Pertussis Vaccine Market Characteristics

3. Pertussis Vaccine Market Trends And Strategies

4. Pertussis Vaccine Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Pertussis Vaccine Market Size and Growth

  • 5.1. Global Pertussis Vaccine Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pertussis Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pertussis Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pertussis Vaccine Market Segmentation

  • 6.1. Global Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine
  • Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine
  • 6.2. Global Pertussis Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Whole-Cell Vaccine
  • Acellular Vaccine
  • 6.3. Global Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Children
  • Adults
  • Infants
  • 6.4. Global Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Vaccination Centers
  • Hospitals
  • Clinics

7. Pertussis Vaccine Market Regional And Country Analysis

  • 7.1. Global Pertussis Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pertussis Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pertussis Vaccine Market

  • 8.1. Asia-Pacific Pertussis Vaccine Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pertussis Vaccine Market

  • 9.1. China Pertussis Vaccine Market Overview
  • 9.2. China Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pertussis Vaccine Market

  • 10.1. India Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pertussis Vaccine Market

  • 11.1. Japan Pertussis Vaccine Market Overview
  • 11.2. Japan Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pertussis Vaccine Market

  • 12.1. Australia Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pertussis Vaccine Market

  • 13.1. Indonesia Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pertussis Vaccine Market

  • 14.1. South Korea Pertussis Vaccine Market Overview
  • 14.2. South Korea Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pertussis Vaccine Market

  • 15.1. Western Europe Pertussis Vaccine Market Overview
  • 15.2. Western Europe Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pertussis Vaccine Market

  • 16.1. UK Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pertussis Vaccine Market

  • 17.1. Germany Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pertussis Vaccine Market

  • 18.1. France Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pertussis Vaccine Market

  • 19.1. Italy Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pertussis Vaccine Market

  • 20.1. Spain Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pertussis Vaccine Market

  • 21.1. Eastern Europe Pertussis Vaccine Market Overview
  • 21.2. Eastern Europe Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pertussis Vaccine Market

  • 22.1. Russia Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pertussis Vaccine Market

  • 23.1. North America Pertussis Vaccine Market Overview
  • 23.2. North America Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pertussis Vaccine Market

  • 24.1. USA Pertussis Vaccine Market Overview
  • 24.2. USA Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pertussis Vaccine Market

  • 25.1. Canada Pertussis Vaccine Market Overview
  • 25.2. Canada Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pertussis Vaccine Market

  • 26.1. South America Pertussis Vaccine Market Overview
  • 26.2. South America Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pertussis Vaccine Market

  • 27.1. Brazil Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pertussis Vaccine Market

  • 28.1. Middle East Pertussis Vaccine Market Overview
  • 28.2. Middle East Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pertussis Vaccine Market

  • 29.1. Africa Pertussis Vaccine Market Overview
  • 29.2. Africa Pertussis Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pertussis Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Pertussis Vaccine Market, Segmentation By End-User , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pertussis Vaccine Market Competitive Landscape And Company Profiles

  • 30.1. Pertussis Vaccine Market Competitive Landscape
  • 30.2. Pertussis Vaccine Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson And Johnson Pvt Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck And Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Pertussis Vaccine Market Other Major And Innovative Companies

  • 31.1. AstraZeneca plc
  • 31.2. BioNTech SE
  • 31.3. Moderna Inc.
  • 31.4. Sinovac Biotech Ltd.
  • 31.5. CSL Limited
  • 31.6. Astellas Pharma US Inc.
  • 31.7. Sanofi Pasteur SA
  • 31.8. Mitsubishi Tanabe Pharma America Inc.
  • 31.9. PT Kalbe Farma Tbk
  • 31.10. CSL Seqirus
  • 31.11. Walvax Biotechnology Co.Ltd.
  • 31.12. Biological E. Limited
  • 31.13. Serum Institute of India
  • 31.14. Bavarian Nordic AS
  • 31.15. PT Bio Farma

32. Global Pertussis Vaccine Market Competitive Benchmarking

33. Global Pertussis Vaccine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pertussis Vaccine Market

35. Pertussis Vaccine Market Future Outlook and Potential Analysis

  • 35.1 Pertussis Vaccine Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Pertussis Vaccine Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Pertussis Vaccine Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer